Advertisement

„Tight control“ – Forderung nach engmaschiger Kontrolle der rheumatoiden Arthritis

  • M. SchneiderEmail author
  • G.-R. BurmesterEmail author
Leitthema
  • 39 Downloads

Zusammenfassung

Die Prognose der rheumatoiden Arthritis (RA) hat sich in den letzten Jahrzehnten deutlich verbessert. Dazu haben im Wesentlichen eine frühere Erkennung, bessere Diagnostik und neue Therapieoptionen wie optimierter Einsatz von klassischen DMARDs („disease modifying antirheumatic drugs“) und Biologika beigetragen. Weitere Faktoren waren auch eine frühere Intervention, eine verbesserte Verfügbarkeit von Informationen und Analysen und sicher auch die Standardisierung der Versorgung (z. B. Leitlinien). Ein zusätzlicher wichtiger Baustein ist eine engmaschige Kontrolle der Krankheitsaktivität, um die Therapie rechtzeitig anpassen zu können und somit Schäden zu verhindern. Die Forderung nach dieser Kontrolle, im englischen „tight control“, ist Gegenstand dieses Beitrags.

Schlüsselwörter

Prognose „Treat to Target“ Therapieoptionen Krankheitsaktivität Disease modifying antirheumatic drugs 

Tight control—Demand for short term control of rheumatoid arthritis

Abstract

The prognosis of rheumatoid arthritis (RA) has been significantly improved in recent decades. This is mainly due to earlier detection, better diagnostics and new treatment options, such as the optimized use of classical disease-modifying antirheumatic drugs (DMARD) and biologicals. Other factors involved were earlier intervention, improved availability of information and analyses and certainly also standardization of care (e.g. guidelines). An additional important component is close monitoring of disease activity in order to be able to adapt the treatment in a timely manner and thus prevent damage. The demand for tight control is the subject of this article.

Keywords

Prognosis Treat to target Treatment options Disease activity Disease-modifying antirheumatic drugs 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Schneider weist auf folgende Beziehungen hin: Projektunterstützung (von Abbvie, GSK, UCB) und Beratung/Vorträge (für Abbvie, Astra-Zeneca, Biogen, BMS, Boehringer-Ingelheim, Celgene, Chugai, GSK, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, Protagen, Roche, Sanofi-Aventis, UCB). G.‑R. Burmester gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Albrecht K, Callhoff J, Edelmann E, Schett G, Schneider M, Zink A (2016) Klinische Remission bei rheumatoider Arthritis. Daten aus der Früharthritiskohortenstudie CAPEA. Z Rheumatol 75(1):90–96CrossRefPubMedGoogle Scholar
  2. 2.
    Aletaha D, Alasti F, Smolen JS (2016) Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3‑month time point. Ann Rheum Dis 75(8):1479–1485CrossRefPubMedGoogle Scholar
  3. 3.
    Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter BEJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388(10042):343–355CrossRefPubMedGoogle Scholar
  4. 4.
    Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, Klop B, Liem AH, vanvde Geijn GM, van der Meulen N, Birnie E, van der Zwan EM, van Zeben J, CastrovCabezas M (2019) Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 4.  https://doi.org/10.1136/annrheumdis-2018-214075 (pii: annrheumdis-2018-214075)CrossRefPubMedGoogle Scholar
  5. 5.
    Cattelaens K, Schewe S, Schuch F (2019) Treat to Target – Beteiligung der Patienten. ZfR.  https://doi.org/10.1007/s00393-019-0629-4 CrossRefGoogle Scholar
  6. 6.
    de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF (2008) Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58(5):1293–1298CrossRefPubMedGoogle Scholar
  7. 7.
    Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR (2013) Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72(6):844–850CrossRefPubMedGoogle Scholar
  8. 8.
    Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70(3):404–413CrossRefPubMedGoogle Scholar
  9. 9.
    Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Se-Leitlinie KK (2018) Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z Rheumatol 77(Suppl 2):35–53CrossRefPubMedGoogle Scholar
  10. 10.
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269 (Jul)CrossRefPubMedGoogle Scholar
  11. 11.
    Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, DaSilva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Moreno SP, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D, Treat to Target Taskforce (2011) Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 70(11):1999–2002CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guérette B, Kupper H, Smolen JS (2018) Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis 77(2):289–292CrossRefPubMedGoogle Scholar
  13. 13.
    Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, Landewé RB, Smolen JS, Sokka T, van der Heijde DM (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69(6):987–994CrossRefPubMedGoogle Scholar
  14. 14.
    Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF (2017) Do short and sustained periods of American college of rheumatology/European league against rheumatism remission predict functional and radiographic outcome in early rheumatoid arthritis patients with low overall damage progression? Arthritis Care Res (hoboken) 69(7):989–996CrossRefGoogle Scholar
  15. 15.
    Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, Berner Hammer H, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA (2018) Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2‑year data from the ARCTIC trial. RMD Open 4(2):e752.  https://doi.org/10.1136/rmdopen-2018-000752 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Norvang V, Brinkmann GH, Sexton J, Aga AB, Lillegraven S, Uhlig T, Kvien T, Mjaavatten MD, Haavardsholm EA (2018) Achievement of remission in two early rheumatoid arthritis inception cohorts implementing different treat-to-target strategies. Arthritis Rheumatol 70(suppl 10)Google Scholar
  17. 17.
    Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA (2018) Predicting achievement of the treatment targets at 6 months from 3‑month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open 4(2):e773.  https://doi.org/10.1136/rmdopen-2018-000773 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pappas DA, Gerber RA, Litman HJ, Gruben D, Geier J, Hua WD, Chen C, Li Y, Kremer JM, Andrews JS, Bourret JA (2018) Delayed treatment acceleration in patients with rheumatoid arthritis who have inadequate response to initial tumor necrosis factor inhibitors: data from the Corrona registry. Am Health Drug Benefits 11(3):148–158PubMedPubMedCentralGoogle Scholar
  19. 19.
    Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M, NEO-RACo Study Group. (2014) Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5‑year followup results of the randomized clinical NEO-RACo trial. J Rheumatol 41(12):2379–2385CrossRefPubMedGoogle Scholar
  20. 20.
    Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15CrossRefPubMedGoogle Scholar
  21. 21.
    Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977CrossRefPubMedGoogle Scholar
  22. 22.
    Solomon DH, Lu B, Yu Z, Corrigan C, Harrold LR, Smolen JS, Fraenkel L, Katz JN, Losina E (2018) Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial. Arthritis Care Res (hoboken) 70(10):1551–1556CrossRefGoogle Scholar
  23. 23.
    ten Klooster PM, Steunebrink LMM, Versteeg L, de la Torre I, de Leonardis F, Fakhouri W, Zaremba-Pechmann L, van de Laar M (2018) Association between disease activity and radiographic progression in the current treat-to-target paradigm of rheumatoid arthritis: real world data from the Dutch rheumatoid arthritis monitoring (DREAM) registry [abstract. Arthritis Rheumatol 70(suppl 10).  https://doi.org/10.1186/s41927-018-0009-8 CrossRefPubMedGoogle Scholar
  24. 24.
    van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J (2012) Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379(9827):1712–1720CrossRefPubMedGoogle Scholar
  25. 25.
    Versteeg GA, Steunebrink LMM, Vonkeman HE, Ten Klooster PM, van der Bijl AE, van de Laar MAFJ (2018) Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol 37(5):1189–1197CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wailoo A, Hock ES, Stevenson M, Martyn-St JM, Rawdin A, Simpson E, Wong R, Dracup N, Scott DL, Young A (2017) The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health Technol Assess 21(71):1–258CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yu C, Jin S, Wang Y, Jiang N, Wu C, Wang Q, Tian X, Li M, Zeng X (2018) Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol.  https://doi.org/10.1007/s10067-018-4340-7 CrossRefPubMedGoogle Scholar
  28. 28.
    Zak A, Corrigan C, Yu Z, Bitton A, Fraenkel L, Harrold L, Smolen JS, Solomon DH (2018) Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. Rheumatology 57(11):1933–1937CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Poliklinik und Funktionsbereich für Rheumatologie und Hiller ForschungszentrumUniversitätsklinikum DüsseldorfDüsseldorfDeutschland
  2. 2.Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische ImmunologieCharité – Universitätsmedizin BerlinBerlinDeutschland

Personalised recommendations